

Cerca Biotech Announces CE Mark of RNXtract®

Cerca Biotech announced that it has obtained a CE mark for RNXtract®, its kit for nucleic acid extraction from FFPE tissues.

BERLIN, GERMANY, November 13, 2023 /EINPresswire.com/ -- [Cerca Biotech](#) GmbH ("Cerca"), a Germany-based diagnostic company in oncology and women's health, today announced that it has obtained a CE mark for [RNXtract®](#), its kit for nucleic acid extraction from FFPE tissues.



We strive to offer better solutions in oncology and women's health through our innovative diagnostic products such as MammaTyper® and RNXtract®"

said Rich Hughes, Commercial Director of Cerca Biotech.

RNXtract® is a proprietary kit developed by Cerca Biotech for the extraction of nucleic acids from FFPE tissues. It is based on magnetic beads and offers superior nucleic acid quality with greater yields. While intended for many applications, it is especially suited for extracting RNA for use with the novel breast cancer subtyping tool [MammaTyper®](#) commercialized by Cerca Biotech. "We are

happy to offer to our customers this new tool for molecular diagnosis using FFPE tissue samples. We strive to offer better solutions in oncology and women's health through our innovative diagnostic products such as MammaTyper® and RNXtract®," said Rich Hughes, Commercial Director of Cerca Biotech.

About MammaTyper®

MammaTyper® is a standardised multiplex real-time PCR test that quantifies mRNA levels of four essential breast cancer biomarkers (ER, PgR, HER2, and Ki-67) in surgical or biopsy tissue to stratify breast cancer into subtypes according to the St Gallen Guideline. Compared to the traditional immunohistochemistry (IHC) subtyping, MammaTyper® is a qPCR assay that provides objective and reproducible test results in a shorter turnaround time and obviates subjective IHC scoring by pathologists. Moreover, a large body of published clinical studies have demonstrated that MammaTyper® offers more accurate breast classification and can guide more effective treatment leading to improved patient outcome.

About Cerca Biotech:

Cerca Biotech is a Germany-based diagnostic company focused on bringing novel and innovative diagnostic products to the oncology and women's health market. We strive to introduce the best

tests to meet the unmet clinical needs at an affordable cost, with clinical accuracy and rapid results to the fore. Utilising a mixture of experienced distributors and some direct sales Cerca has a commercial reach from Germany, the UK through the Nordics and Eastern Europe to the Middle East, India and beyond. Our team comprises of highly experienced commercial, technical and clinical experts in the field of IVD, allowing rapid deployment of novel technologies with a 'get it right first time' strategy. Cerca Biotech is an affiliated subsidiary of Shuwen Biotech. For more information, please visit: www.cercabiotech.com.

Richard Hughes
Cerca Biotech GmbH
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/668136712>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.